Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Interferential current poised to become new treatment option for POI

01 Apr 2020

Perineal interferential current (IC) proves beneficial in the treatment of women with premature ovarian insufficiency (POI) who are using systemic hormone therapy (HT) and presenting with sexual complaints, with the results of a 4-week trial showing that IC yields favourable effects on pain, lubrication, satisfaction and orgasm as compared with topical estriol.

A total of 40 women (mean age, 37.13 years) with POI were randomly assigned to receive eight electrotherapy sessions (administered twice a week; IC group) or treatment with estriol vaginal cream (daily application, 0.5 mg/d; E group). All women were sexually active and were using systemic HT (mean duration of treatment, 8.20 years), and had been referred for dyspareunia and reduction of lubrication.

Researchers used the Female Sexual Function Index to evaluate pre- and post-treatment sexual function. They noted improvements in global sexual function, lubrication and pain domains for both IC and E groups post-treatment.

The differences between the pre- and post-treatment scores were significant in both the IC and E groups, namely for lubrication (mean, 0.75; p=0.014 and mean, 1.16; p<0.001) and for dyspareunia (mean, 1.00; p=0.005 and mean, 0.68; p=0.006). There were no changes seen for the desire and arousal domains.

Finally, compared with E, IC had superior effects on orgasm (mean difference, 0.90; p=0.010) and satisfaction (mean difference, 0.70; p=0.021).

The present data suggest that perineal IC provides a new option in the treatment of POI patients with sexual complaints, the researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.